F-1/A: Altamira Therapeutics Announces Proposed Offering of Common Shares and Warrants

Altamira Therapeutics plans to offer up to 5,952,380 common shares, pre-funded warrants, and associated warrants in a public offering.

Summary

• Altamira Therapeutics Ltd. is planning a public offering of up to 5,952,380 common shares along with Series A-1 and A-2 warrants to purchase an equal number of common shares.
• The assumed combined public offering price is $0.84 per common share and accompanying warrants, based on the closing price on September 13, 2024.
• Pre-funded warrants to purchase up to 5,952,380 common shares are also being offered to investors who would exceed a 4.99% or 9.99% ownership threshold after the offering.
• The exercise price for the pre-funded warrants will be $0.002 per common share.
• H.C. Wainwright & Co., LLC is acting as the exclusive placement agent for the offering.
• The company intends to use the net proceeds from this offering for working capital and general corporate purposes.
• The Series A-1 Warrants will expire on the earlier of the eighteen-month anniversary of the original issuance date or 60 days following the occurrence of Milestone 1.
• The Series A-2 Warrants will expire on the earlier of the five-year anniversary of the original issuance date or six months following the occurrence of Milestone 2.

Sentiment

Score: 4

Explanation: The document is primarily factual and descriptive, but the inclusion of risk factors and the mention of going concern uncertainty temper the sentiment.

Positives

• The offering will provide Altamira Therapeutics with additional working capital.
• The company has engaged an experienced placement agent, H.C. Wainwright & Co., LLC.
• The offering includes warrants, which could provide additional capital to the company upon exercise.
• The company has broad discretion in how it uses the net proceeds of this offering.

Negatives

• There is no minimum offering amount required, so the company may raise less capital than anticipated.
• Investors will experience immediate and substantial dilution in the net tangible book value of their shares.
• There is no public market for the pre-funded warrants or common warrants.
• The company needs to raise capital in this offering to support its operations, and there is substantial doubt about its ability to continue as a going concern.

Risks

• Investing in the company's securities involves a high degree of risk.
• The company may not raise the amount of capital it believes is required for its business plans.
• Investors will incur immediate and substantial dilution in the net tangible book value of their common shares.
• There is no public market for the pre-funded warrants or the common warrants.
• The company may be involuntarily delisted from trading on The Nasdaq Capital Market if it fails to comply with the continued listing requirements.
• If the company is or becomes classified as a passive foreign investment company (PFIC), U.S. shareholders may suffer adverse tax consequences.
• There is substantial doubt about the company's ability to continue as a going concern.

Future Outlook

The company intends to use the net proceeds from this offering for working capital and general corporate purposes.

Industry Context

The announcement reflects a common financing strategy for preclinical-stage biopharmaceutical companies to raise capital for ongoing research and development.

Comparison to Industry Standards

• Comparable companies in the biopharmaceutical sector, such as Aurinia Pharmaceuticals Inc. and Corcept Therapeutics Incorporated, often utilize public offerings to fund clinical trials and research programs.
• The terms of the offering, including the use of warrants, are consistent with industry practices for companies with similar market capitalizations and development stages.
• The engagement of H.C. Wainwright & Co., LLC as a placement agent is typical for companies seeking to access capital markets.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• The company's ability to fund its research and development programs will be enhanced.
• The offering could improve the company's financial stability and long-term prospects.

Next Steps

• The company will proceed with the public offering, subject to market conditions and regulatory approvals.
• The company will use the net proceeds for working capital and general corporate purposes.
• The company will need to meet the milestones associated with the warrants to avoid early expiration.

Key Dates

Keywords

common shares, warrants, public offering, pre-funded warrants, placement agent, Altamira Therapeutics, offering